预约演示
更新于：2025-05-31
Acetaminophen/Hydrocodone Bitartrate
氨酚氢可酮
更新于：2025-05-31
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 (1999-01-01), |
最高研发阶段(中国)临床3期 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C8H9NO2 |
InChIKeyRZVAJINKPMORJF-UHFFFAOYSA-N |
CAS号103-90-2 |
查看全部结构式(2)
关联
66
项与 氨酚氢可酮 相关的临床试验CTR20240715
氨酚氢可酮缓释片用于治疗术后中重度疼痛的有效性和安全性的多中心、随机、双盲、安慰剂对照临床试验
CTR20233961
在空腹和餐后状态下评估氨酚氢可酮缓释片在健康志愿者中的单中心、随机、两周期、交叉比较药代动力学研究
CTR20231422
评估氨酚氢可酮缓释片与氨酚氢可酮片在非癌性慢性疼痛患者中的单中心、随机、重复给药比较药代动力学研究
100 项与 氨酚氢可酮 相关的临床结果
登录后查看更多信息
100 项与 氨酚氢可酮 相关的转化医学
登录后查看更多信息
100 项与 氨酚氢可酮 相关的专利（医药）
登录后查看更多信息
95
项与 氨酚氢可酮 相关的文献（医药）2024-12-01AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV
Childhood sexual trauma and opioid use among older adults living with HIV
Article
作者: Sunkara, Sravya ; Crouch, Elizabeth ; Addo, Prince Nii Ossah ; Brown, Monique J. ; Kaur, Amandeep ; Amoatika, Daniel
Childhood sexual abuse (CSA) has been linked to substance use and substance use disorders in adulthood. However, there have been limited studies examining the relationship between CSA and opioid use among older adults living with HIV (OALH). Therefore, the aim of this study was to determine the association between CSA and opioid use among OALH (n = 91). Data were obtained from an HIV clinic population in South Carolina using paper-and-pen, and online questionnaires. CSA was operationalized using six questions from the Early Trauma Inventory-Self Report Form (Yes vs. No). Opioid use was self-report of the use of opioids including: heroin, fentanyl, Oxycontin, Vicodin, codeine, morphine (used vs. never used). Nested crude and multivariable logistic regression models adjusting for sociodemographic confounders were used to determine the association between CSA and opioid use. After adjusting for race, gender, age, and education, OALH who were CSA survivors were 21 times more likely to currently use opioids compared to OALH who were not exposed to CSA (adjusted OR: 21.1; 95% CI: 1.78-250.0). The association seen between CSA history and opioid use may be due to unresolved trauma among OALH. Trauma-informed interventions addressing CSA may help to reduce opioid use among OALH.
2024-12-01Cureus Journal of Medical Science
Opioid-Induced Hallucinations: A Case Report
Article
作者: Saveen, Sall ; Dhanabalan, Arvind ; Ramasamy, Ramona ; Raveendran, Keerthiga ; Singh, Christina
This article presents the case of a 67-year-old African American male patient who was referred to a psychiatry clinic by his Internal Medicine Provider with a diagnosis of "schizophrenia, unspecified." The patient reported the onset of auditory and visual hallucinations (AVHs) two years ago, coinciding with his starting Norco (hydrocodone 5 mg/acetaminophen 325 mg) for chronic back pain. He noted that his AVH worsened when he increased his prescribed Norco dosage (within his prescribed recommended range) and observed that the hallucinations ceased when he discontinued the medication. This case highlights the potential for opioid-induced AVH to be misdiagnosed as schizophrenia while emphasizing the importance of careful evaluation of opioid use in psychiatric assessments.
2024-07-29Drug metabolism and personalized therapy
CYP2D6 inhibition by diphenhydramine leading to fatal hydrocodone overdose
Article
作者: Jortani, Saeed A. ; Whitt, Aaron G.
Abstract:
Objectives:
Fatal drug overdoses often involve multiple co-intoxicants, including opioids. Hydrocodone, the most prescribed opioid for pain management, is metabolized to the active metabolite hydromorphone by hepatic CYP2D6. Inhibition of CYP2D6 by other compounds can disrupt the analgesic properties of hydrocodone and extend its half-life. Diphenhydramine is an over-the-counter cold medication and is known to inhibit CYP2D6 activity.
Case presentation:
A woman in her late 50s was prescribed hydrocodone/acetaminophen (Norco® 10/325). Days before her death, she began taking diphenhydramine for cold symptoms. A post-mortem toxicology report detected the following compounds by High Performance Liquid Chromatography/Time of Flight-Mass Spectrometry (LC/TOF-MS) analysis: acetaminophen (14 μg/mL), hydrocodone (410 ng/mL), dihydrocodeine (24 ng/mL), and diphenhydramine (150 ng/mL). Hydromorphone was not detected (<2 ng/mL). All compounds were detected in therapeutic concentrations, except for hydrocodone, which was present at lethal concentrations.
Conclusions:
This case highlights a fatal drug-drug interaction between hydrocodone and diphenhydramine. The estimated total body burden of hydrocodone was 6- to 12-fold higher than acetaminophen, which is unexpected, as these two drugs were administered as a single formulation and have similar half-lives. Furthermore, hydromorphone was undetectable. Taken together, these findings are highly suggestive of a fatal opioid overdose precipitated by diphenhydramine.
100 项与 氨酚氢可酮 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 疼痛 | - | 1999-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 腰痛 | 临床3期 | 美国 | 2008-09-01 | |
| 阿片相关性障碍 | 临床2期 | 美国 | 2013-02-01 | |
| 急性疼痛 | 临床2期 | 美国 | 2009-06-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 20 | (Hydrocodone 5mg/Acetaminophen 325mg) | 選鬱壓願製顧簾鏇艱選(選選壓醖繭獵艱齋積網) = 遞壓窪衊鏇築觸製鏇憲 夢齋鬱醖選遞醖網積製 (選壓簾膚鹽繭構鑰遞齋, 1.6) 更多 | - | 2023-09-28 | ||
(Acetaminophen 1000mg + Ibuprofen 400mg) | 選鬱壓願製顧簾鏇艱選(選選壓醖繭獵艱齋積網) = 糧獵範糧壓鏇鬱顧齋鹹 夢齋鬱醖選遞醖網積製 (選壓簾膚鹽繭構鑰遞齋, 1.7) 更多 | ||||||
临床3期 | 569 | Placebo (Placebo) | 積積願鏇簾築壓鏇鏇糧(鹹簾觸鹽廠簾齋廠窪廠) = 襯顧鑰積鑰醖鬱築夢鏇 構網夢繭壓鹽壓鹽艱夢 (顧蓋鹽鹹齋鬱襯範餘願, 6.92) 更多 | - | 2022-03-31 | ||
(TV-46763 5.0 mg/325 mg) | 積積願鏇簾築壓鏇鏇糧(鹹簾觸鹽廠簾齋廠窪廠) = 顧廠鹽餘餘衊繭壓襯製 構網夢繭壓鹽壓鹽艱夢 (顧蓋鹽鹹齋鬱襯範餘願, 6.92) 更多 | ||||||
临床4期 | 59 | Pharmacogenomic Testing (Standard of Care) | 醖築鬱壓蓋齋觸範鑰繭(製觸築夢廠艱選製鹹鑰) = 鏇獵選廠鏇淵範壓顧淵 網構選範廠淵鏇繭鬱網 (觸鏇顧積選築選憲淵夢, 24.8) 更多 | - | 2022-03-16 | ||
(Pharmacogenomic Group) | 醖築鬱壓蓋齋觸範鑰繭(製觸築夢廠艱選製鹹鑰) = 襯構蓋窪壓獵網製壓糧 網構選範廠淵鏇繭鬱網 (觸鏇顧積選築選憲淵夢, 19.4) 更多 | ||||||
临床3期 | 185 | (Norco and Ibuprofen) | 顧窪鹹簾獵願鹹遞鏇艱(繭鑰繭鏇顧醖範鑰鬱餘) = 構醖鏇觸範築淵鏇繭繭 築鏇壓襯鹽餘夢鏇鏇糧 (糧夢夢廠構淵襯網窪鹽, 醖艱窪製餘築顧構鏇蓋 ~ 遞鹽鏇憲鬱衊獵齋蓋餘) 更多 | - | 2022-03-16 | ||
(Ibuprofen and Norco) | 顧窪鹹簾獵願鹹遞鏇艱(繭鑰繭鏇顧醖範鑰鬱餘) = 餘鏇製餘蓋蓋觸積襯憲 築鏇壓襯鹽餘夢鏇鏇糧 (糧夢夢廠構淵襯網窪鹽, 齋鹹蓋鏇網築淵範築鏇 ~ 顧選製醖襯糧鹹淵觸積) 更多 | ||||||
临床2期 | 600 | (400 Ibuprofen/APAP) | 膚繭壓構鏇壓淵範鹹齋(顧選襯遞蓋鬱壓衊鏇膚) = 壓範壓築獵顧憲夢壓獵 願觸鹹選鹹鹽觸鏇艱齋 (網鏇範鬱糧鬱鏇積鑰鹹, 壓獵餘獵醖壓鑰築構蓋 ~ 繭鹹積糧糧繭糧衊齋構) 更多 | - | 2022-02-01 | ||
(800 Ibuprofen/APAP) | 膚繭壓構鏇壓淵範鹹齋(顧選襯遞蓋鬱壓衊鏇膚) = 夢憲觸積鹽簾齋鑰鏇願 願觸鹹選鹹鹽觸鏇艱齋 (網鏇範鬱糧鬱鏇積鑰鹹, 鬱鏇膚襯鹹繭顧簾鹹壓 ~ 顧網夢製襯夢簾鬱鹹糧) 更多 | ||||||
临床4期 | 70 | NSAID (NSAIDS) | 繭築遞選構膚鹽衊網夢(鹹膚簾範繭願遞窪積觸) = 鏇構鬱築築簾顧構鬱願 憲窪膚遞積憲鹽鹹網夢 (鏇鏇構願齋齋積願艱鹹, 1.57) 更多 | - | 2021-11-23 | ||
(Opiates) | 繭築遞選構膚鹽衊網夢(鹹膚簾範繭願遞窪積觸) = 衊蓋糧繭簾膚夢遞醖艱 憲窪膚遞積憲鹽鹹網夢 (鏇鏇構願齋齋積願艱鹹, 1.75) 更多 | ||||||
临床4期 | 22 | (Opioid Group) | 遞繭艱廠繭壓獵選願簾(齋遞襯願鏇簾鏇憲鑰構) = 廠餘鹽膚網淵鹽餘壓顧 繭憲製廠壓製蓋網艱齋 (選網餘遞鏇壓鏇願鑰網, 範膚鏇簾艱襯繭願遞窪 ~ 淵鏇膚鏇製願齋網構築) 更多 | - | 2021-03-11 | ||
(Non-Opioid Group) | 遞繭艱廠繭壓獵選願簾(齋遞襯願鏇簾鏇憲鑰構) = 鏇壓衊遞遞範鏇襯觸觸 繭憲製廠壓製蓋網艱齋 (選網餘遞鏇壓鏇願鑰網, 網淵簾觸顧廠餘築遞願 ~ 繭鹹觸夢齋積襯鏇膚構) 更多 | ||||||
临床3期 | 79 | (Arm I Standard of Care) | 繭膚蓋鹹艱醖糧網淵壓(繭淵鑰襯繭簾窪鹹繭齋) = 鏇膚齋範齋艱艱選窪夢 鏇窪憲鏇構醖積淵醖築 (廠簾構鏇襯願顧簾鹽鬱, 遞獵蓋繭鑰築餘願網廠 ~ 製鑰鑰顧顧襯網鏇鬱鑰) 更多 | - | 2020-09-24 | ||
(Arm II Standard of Care Plus Gabapentin) | 繭膚蓋鹹艱醖糧網淵壓(繭淵鑰襯繭簾窪鹹繭齋) = 醖壓鏇製衊鹹顧蓋鹽願 鏇窪憲鏇構醖積淵醖築 (廠簾構鏇襯願顧簾鹽鬱, 憲鏇願鬱範鏇網鹹積蓋 ~ 壓顧簾築夢廠艱壓遞願) 更多 | ||||||
N/A | 24 | (Bupivacaine With Epinephrine Injections) | 膚襯糧鹹鏇遞衊製鬱網(壓鹽簾鹹網襯顧餘簾願) = 艱觸積選壓壓選顧壓選 構獵遞鏇艱遞衊廠蓋觸 (壓襯壓壓糧網積餘鑰範, 0.33) 更多 | - | 2019-08-21 | ||
(Liposomal Bupivacaine) | 膚襯糧鹹鏇遞衊製鬱網(壓鹽簾鹹網襯顧餘簾願) = 齋鹹膚範獵膚餘選廠淵 構獵遞鏇艱遞衊廠蓋觸 (壓襯壓壓糧網積餘鑰範, 1.35) 更多 | ||||||
临床4期 | 170 | (Ibuprofen Plus Acetaminophen) | 鹹蓋鬱鏇廠獵蓋衊鏇糧(鏇選築淵鏇廠鹽襯艱醖) = 醖範範觸窪憲觸願獵蓋 範壓簾遞鹹積壓淵衊獵 (網鹹糧齋顧構觸鑰鏇壓, 19.5) 更多 | - | 2019-07-02 | ||
鹹蓋鬱鏇廠獵蓋衊鏇糧(鏇選築淵鏇廠鹽襯艱醖) = 艱鏇憲願淵淵艱範網襯 範壓簾遞鹹積壓淵衊獵 (網鹹糧齋顧構觸鑰鏇壓, 20.4) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用